Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncology

Set Alert for Oncology

Blueprint RETreats As It Sells US Gavreto Rights To Rigel

After sales of the RET inhibitor have been commercially disappointing, Blueprint said it is selling US rights to the drug to Rigel for $15m up front and potentially more than $100m in milestones.

Business Strategies Deals

Arcus And Gilead Make GI Cancers The Focus Of Their TIGIT Hopes

Gilead ups its investment in its TIGIT partner, as the firms pivot to a less crowded market opportunity in upper GI cancers.

Companies Cancer

BMS Looks For Krazati KRAS Lead After Amgen’s Stumble

Success in a confirmatory study and in combination with Keytruda could seal BMS’s best-in-class claims.

Companies Clinical Trials

Toward The Global Big Pharma League: Yuhan’s Ambitions After Leclaza

With Leclaza as a foothold, the next couple of years will be crucial for Yuhan’s ambition to become a top 50 global pharma firm. R&D president Yeul Hong Kim shares how he intends to shape the leading Korean company's efforts to compete with its global rivals.

South Korea Business Strategies

Dato-DXd Filing Lifts Mood For AstraZeneca Investors

AstraZeneca and Daiichi-Sankyo are targeting only non-squamous patients with their first Dato-DXd filing, but are still on course for a first-in-class approval by year end.

Companies Clinical Trials

Iovance Lucks Out With Amtagvi

The long-delayed accelerated approval of the melanoma T-cell therapy comes a week early, and with a generous label.

Approvals Cancer

From Ranbaxy Crisis To Enhertu Success: How A New CEO Reshaped Daiichi Sankyo

When George Nakayama was assigned to lead Daiichi Sankyo despite his atypical background, the firm was facing several crises, including a probe into the acquisition of Ranbaxy and a looming patent cliff. So, what made him decide to focus on ADCs while reshaping the entire company? 

Leadership Strategy

Genmab On The Hunt For Late-Stage Assets

The Danish biotech has dipped its toe into co-commercialization recently and is seeking more candidates that are getting closer to the market.

Sales & Earnings M & A

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies

AstraZeneca Outlines Growth Ambitions – Could This Include Oncology Leadership By 2030?

Not content with fulfilling its decade-long $45bn sales target, AstraZeneca is now preparing for Act 2: a new 10-year 'cycle of growth'.

Sales & Earnings Companies

Ipsen In No Doubt About Its Abilities To Launch

Sales of the French firm’s new products missed consensus forecasts but CEO David Loew is confident that those drugs and the therapies that are close to the market will be commercial successes.

Sales & Earnings Business Strategies

Japan Q3 Roundup: Daiichi Emerges As Growth Leader While Others Balance Ups And Downs

The success of Enhertu led Daiichi Sankyo to raise its annual forecast for the fiscal year ending 31 March, while Eisai is readying for Leqembi’s steady US growth. Meanwhile, Astellas, Chugai and Shionogi balanced growth for some products with declines for others.

Japan Sales & Earnings

Resilient Redx Inks Jazz KRAS Pact

The UK biotech has teamed up again with Jazz, banking a $10m upfront fee that will help towards advancing its wholly owned ROCK inhibitor program for fibrosis indications.

Deals Cancer

China Biotech Interview: BeiGene Co-Founder Wang Eyes Next Big Things

BeiGene co-founder and chair of the major global biotech's Scientific Advisory Board, Dr. Xiaodong Wang, sits down with Scrip in an exclusive audio interview to shed light on the rapid rise of China's biotech innovation, the country's role in BeiGene's global strategy and the next big things to watch.

China Business Strategies

Novartis Makes An Ideal Match For MorphoSys

The Swiss major looks to have bagged a bargain in buying MorphoSys and its potential game-changer myelofibrosis candidate pelabresib.

M & A Cancer

Encouraging Phase III Data For Blenrep But GSK Remains Cautious On Market Return

Data may prove too little too late for the antibody drug conjugate, as GSK takes a cautious stance over future commercial viability.

Commercial Clinical Trials
See All
UsernamePublicRestriction

Register